The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Education
  • Legal
  • Construction
  • Entertainment
  • Non-profit

Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
The PennZone/10233330

Trending...
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several investor conferences in June 2023. These investor conferences include:

Jefferies Global Healthcare Conference
  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
  • Friday, June 9 at 10:00 am EDT.
  • New York City

Baird's Biotech Discovery Series
  • Steven Kelly, President and Chief Executive Officer, and Michael Klichinsky, PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.
  • Wednesday, June 21 at 1:30 pm EDT.
  • Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts will be archived at the Company's past events section of the Investor Relations webpage for a limited time following the event.

About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

More on The PennZone
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Colbert Packaging Announces WBENC Recognition
  • SHI Cryogenics Group Launches Highest-Capacity Single-Stage Cryocoolers to Date
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management

Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma in future healthcare industry and investor conferences. The words ""anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's most recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

More on The PennZone
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

Investor Contact:
[email protected]

SOURCE Carisma Therapeutics Inc.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Greenlight Networks to Acquire Loop Internet
  • Finding the Best AC Repair Service in Philadelphia
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Phillie Phanatic Joins the Together We Dance Foundation's Summer Dance Team to Celebrate Inclusion
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • CLASS ACTION NOTICE: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Class Action
  • e4health Earns 2025-2026 Great Place To Work Certification™ for Fourth Consecutive Year
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit

Popular on PennZone

  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • JOSHWAY Launches Children's Book, "JOSHWAY and the Power of Resilience"

Similar on PennZone

  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Franchise-Ready: Wise Business Plans Partners with Leading Franchisors to Support New Franchisees
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • LDR Partners LP Announces Acquisition of Active Radiator, and Combination with Cincinnati Radiator and Ohio Heat Transfer, Forming the Largest U.S. Heavy Manufacturing Platform for Aluminum Industrial Heat Exchangers
  • Sidney and Caroline Kimmel Invest in the Future of Care and Discovery at Jefferson
  • Adostics & Genmega Announce the Introduction of A-POD
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us